246 related articles for article (PubMed ID: 38501360)
1. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors.
Yuan G; Ye M; Zhang Y; Zeng X
Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178
[TBL] [Abstract][Full Text] [Related]
2. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
[TBL] [Abstract][Full Text] [Related]
3. Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors.
Shi T; Sun M; Tuerhong S; Li M; Wang J; Wang Y; Zheng Q; Zou L; Lu C; Sun Z; Zou Z; Shao J; Du J; Li R; Liu B; Meng F
Biomaterials; 2024 Sep; 309():122607. PubMed ID: 38759487
[TBL] [Abstract][Full Text] [Related]
4. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract][Full Text] [Related]
6. Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity.
Hu Y; Sarkar A; Song K; Michael S; Hook M; Wang R; Heczey A; Song X
Cell Rep Med; 2024 May; 5(5):101530. PubMed ID: 38688275
[TBL] [Abstract][Full Text] [Related]
7. CAR-T cell-derived exosomes: a new perspective for cancer therapy.
Sani F; Shojaei S; Tabatabaei SA; Khorraminejad-Shirazi M; Latifi M; Sani M; Azarpira N
Stem Cell Res Ther; 2024 Jun; 15(1):174. PubMed ID: 38886844
[TBL] [Abstract][Full Text] [Related]
8. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
9. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Front Immunol; 2021; 12():738456. PubMed ID: 34721401
[TBL] [Abstract][Full Text] [Related]
10. Targeting metabolism to improve CAR-T cells therapeutic efficacy.
Liu S; Zhao Y; Gao Y; Li F; Zhang Y
Chin Med J (Engl); 2024 Apr; 137(8):909-920. PubMed ID: 38501360
[TBL] [Abstract][Full Text] [Related]
11. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
[TBL] [Abstract][Full Text] [Related]
12. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.
Shen L; Xiao Y; Tian J; Lu Z
Cancer Lett; 2022 Mar; 529():139-152. PubMed ID: 35007698
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
14. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
